https://www.selleckchem.com/pr....oducts/tinengotinib.
To confirm the diagnosis, pathological morphology and immunophenotypic features of the biopsy specimens were observed. The patient denied any history of skin tumors. No abnormal lesions were detected in other sites of the body. Molecular testing was positive for wild-type and gene mutations. Finally, the clinical and pathological findings suggested PMML. PMML is very rare, and the percutaneous biopsy tissue is limited. Therefore, comprehensive consideration of histology, immunohistochemistry, imaging, and clinical information is im
Like
Comment
Share
